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The contribution of the innate immune response to the resolution of Clostridium difficile infection (CDI) re-
mains incompletely defined. In this issue ofCell Host &Microbe, Abt et al. demonstrated that innate lymphoid
cells and the effector cytokine IFN-g are important for recovery from the acute phase of CDI.Clostridium difficile causes 453,000 infec-
tions and 29,000 deaths annually in the
United States, stressing the need for bet-
ter treatment strategies. C. difficile is a
spore-forming, Gram-positive, toxin-pro-
ducing anaerobe that infects the gut
when the natural flora has been disrupted,
primarily through the use of antibiotics.
Once colonization of C. difficile occurs,
its major virulence factors, toxins A and
B, inactivate intestinal epithelial cell Rho
GTPases, leading to cell death and barrier
disruption. Additionally, toxin signaling is
central to the activation of the inflamma-
some (Cowardin et al., 2015). Toxin activ-
ity on the intestinal barrier induces the
recruitment of inflammatory cells to the
colonic lamina propria. However, our un-
derstanding of the consequences of this
inflammatory cascade remains incom-
plete. Studies have demonstrated that
the lack of specific innate immune media-
tors, such as IL-22 and MyD88, leads to
increased mortality in mice, suggesting
that innate immunity aids in host defense
(Hasegawa et al., 2014; Jarchum et al.,
2012). On the other hand, clinical studies
correlate increased pro-inflammatory
markers, such as IL-8, with enhanced dis-
ease severity, and IL-23 signaling in-
creases mortality in the mouse model (El
Feghaly et al., 2013; Buonomo et al.,
2013). Together, these studies suggest
that the activation of innate immunity is
a double-edged sword, and immune
cells likely play multifaceted roles during
C. difficile infection (CDI). It is plausible
that the subsets of immune cells activated
and the effector molecules they produce
may dictate the outcome of CDI. There-
fore, it is important to understand which
innate and adaptive immune cell subsetscontribute to host protection or, con-
versely, enhance pathology during CDI.
In this issue of Cell Host & Microbe, Abt
et al. (2015) provide evidence in a mouse
model of CDI for a beneficial role for
innate lymphoid cells (ILCs) in the resolu-
tion of the acute-phase C. difficile colitis.
ILCs are divided into three groups based
on the transcription factors they express
and the cytokines that they produce.
Group 1 ILCs (ILC1s) produce cytokines
comparable to Th1 cells and are charac-
terized by IFN-g release. Group 2 ILCs
(ILC2s) produce Th2-like cytokines,
including IL-5 and IL-13, and aid in hel-
minth defense. Lastly, similar to Th17
cells, Group 3 ILCs (ILC3s) produce IL-
17 and IL-22 and have an important role
in promoting resistance to certain bacte-
rial infections in the intestine. ILCs can
facilitate a protective innate immune
response to defend against pathogens
and mediate tissue repair, but can also
have negative off-target effects, resulting
in host pathology (Artis and Spits, 2015).
There is limited knowledge on the role of
ILCs during CDI. Geiger et al. (2014)
showed that Nfil3/ mice lacking all
three groups of ILCs have enhanced sus-
ceptibility to infection. Abt et al. (2015)
build upon this knowledge to provide
valuable insight into the mechanism
through which these cells may aid in
host recovery and have identified the sub-
set of ILCs that play the primary role in this
process.
Abt et al. (2015) utilized the mouse
model of CDI to investigate the role of
ILCs in facilitating host recovery from dis-
ease. This mouse model specifically eval-
uated the role of ILCs during the acute
phase of CDI. Mice were challenged orallyCell Host & Micwith a low dose of C. difficile spores
following pretreatment with three antibi-
otics. In agreement with Geiger et al.
(2014), the authors of this study demon-
strated that ILCs were essential to the re-
covery of CDI. The loss of protection was
evident through an increased mortality
rate in Raggc/ mice, which lack ILCs
in addition to mature T and B cells,
compared to both Rag1/ mice, which
only lack mature T and B cells, and wild-
type C57BL/6 mice. Interestingly, sus-
ceptible Raggc/ mice did not have
increased C. difficile bacterial burden or
toxin production, suggesting the loss of
protection occurs via the action of ILCs
on the host and not C. difficile directly.
Next, the authors investigated which cy-
tokines downstream from ILCs were
impaired during infection in Raggc/
mice. Interestingly, Raggc/ mice pro-
duced significantly less IFN-g and IL-22
in response to CDI, indicative of reduced
ILC1 and ILC3 function, compared to
C57BL/6 and Rag1/ mice. Th2-like cy-
tokines such as IL-5 and IL-13 were not
upregulated during infection in any of the
three strains investigated, suggesting
ILC1 and ILC3s, but not ILC2s, were
involved in resolution from infection. The
authors later observed that ILCs were
the primary source of both IFN-g and IL-
22 during infection in Rag/ mice.
Restoration of ILC function through
adoptive transfer of ILCs to Raggc/
mice significantly protected recipients
from C. difficile-associated morbidity
and mortality. While this experiment sup-
ported a beneficial contribution of ILCs,
it remained unclear which group of ILCs
made the largest impact on host defense.
To investigate the involvement of specificrobe 18, July 8, 2015 ª2015 Elsevier Inc. 5
Cell Host & Microbe
PreviewsILC subsets, the authors first evaluated
the role of ILC3s during the resolution of
disease. The authors analyzed weight
loss and survival of Rorc/ mice, which
are devoid of ILC3s, and did not observe
significant differences. Rorc/ mice do
not specifically lack ILC3s, but are also
without lymphoid structures and have an
irregular T cell compartment, making
these results hard to interpret. Interest-
ingly, the lack of downstream cytokines
of ILC3s, IL-22 or IL-17A, had a modest
impact in enhancing weight loss when
compared to control mice. These results
suggest that while ILC3s may play a
minor role in the recovery from infection
in this model of CDI, it is likely that other
ILC subsets are more important to this
process.
Abt et al. (2015) proceeded to elegantly
identify ILC1s as the principal subset of
ILCs that are important in host defense.
The authors utilized Rag1/ Tbet/
mice that are deficient in ILC1s. These
mice recapitulated the phenotype seen
in Raggc/ mice, evidenced by in-
creased mortality and disease severity.
On day 2 of infection, IFN-g levels were
significantly reduced in Rag1/ Tbet/
mice, prompting the authors to investi-
gate the relative contribution of IFN-g in
ILC1-mediated disease resolution. In the
concluding experiment, the investigators
observed increased morbidity and mor-
tality in Rag.IFNg dKO mice compared
to Rag1/ mice. This work signifies that
the loss of IFN-g signaling alone in
Rag1/ mice is enough to phenocopy
the impaired host defense seen in
Raggc/ mice. Together, these experi-
ments implicate IFN-g as an effector
molecule produced by ILC1s that medi-
ates host recovery from acute phase of
CDI. Whether ILC1s are the only cells or
whether other subsets, such as classical6 Cell Host & Microbe 18, July 8, 2015 ª2015NK cells, contribute to IFN-g production
during CDI remains to be clarified.
The work of Abt et al. (2015) raises
awareness of the importance of the innate
immune response during CDI by estab-
lishing that ILCs participate in host recov-
ery from the acute phase of infection. The
study identifies ILC1s as the chief subset
mediating host protection in this model
of CDI and IFN-g production as the
mechanism through which this occurs.
As the authors acknowledge, variation in
the CDI mouse model specifically with re-
gards to the gut microbiota, antibiotic
treatment, and spores versus vegetative
bacterial challenge can result in different
outcomes. Adding to the complexities of
studying this disease, there are numerous
C. difficile strains with varying virulence
factors, including strains that produce a
third toxin, C. difficile transferase or
CDT. From this study we can conclude
that ILC1s and IFN-g have a role to play
in host recovery from CDI. Further exami-
nation into the function of ILC1s across
varying CDI models will highlight stages
of disease that may benefit from therapies
targeting these cells.
This study brings to light the possibility
that different aspects of the immune
response may be beneficial during
different times of disease progression.
Antibodies directed against toxins A and
B reduce relapse rates and symptoms in
patients colonized with C. difficile (Kong
et al., 2015; Goldberg et al., 2015), while
the experiments in this study emphasize
the crucial role of innate immunity. Inves-
tigation into the interplay between the
innate and adaptive immune response is
needed to parse out the respective roles
of both arms of immunity during primary
and recurrent CDI. Lastly, an especially
interesting question that remains from
this study is how IFN-g mediates host re-Elsevier Inc.covery and upon which cells it primarily
exerts its effects. In-depth analysis into
the mechanisms by which ILC1s and
IFN-g aid in host recovery may lead to
the development of better treatment op-
tions for this deadly disease.ACKNOWLEDGMENTS
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